-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Windtree Therapeutics Inc /De/ quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2020 to 2023.
- Windtree Therapeutics Inc /De/ Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$11.8M, a 79.2% decline year-over-year.
- Windtree Therapeutics Inc /De/ annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$20.3M, a 50% increase from 2022.
- Windtree Therapeutics Inc /De/ annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$40.6M, a 47.7% increase from 2021.
- Windtree Therapeutics Inc /De/ annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$77.6M, a 138% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)